CompletedNCT02161718
A Study of ALKS 3831 in Subjects With Schizophrenia and Addiction
Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 70 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: May 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 300
- Sponsor
- Alkermes, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Bulgaria, Poland
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02161718
- Official title
Show the full official title
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Recruitment & locations
CompletedLittle Rock, United States · Springdale, United States · Anaheim, United States
62 more locations
- Culver City, United States
- Garden Grove, United States
- Irvine, United States
- La Jolla, United States
- Long Beach, United States
- National City, United States
- Oakland, United States
- Oceanside, United States
- Orange, United States
- San Diego, United States
- San Francisco, United States
- Torrance, United States
- Washington D.C., United States
- Fort Lauderdale, United States
- Leesburg, United States
- Maitland, United States
- Miami, United States
- North Miami, United States
- Oakland Park, United States
- Orlando, United States
- Tampa, United States
- Atlanta, United States
- Augusta, United States
- Decatur, United States
- Chicago, United States
- Hoffman Estates, United States
- Oak Brook, United States
- Shreveport, United States
- Worcester, United States
- Flowood, United States
- Creve Coeur, United States
- Kansas City, United States
- St Louis, United States
- Las Vegas, United States
- Claremont, United States
- Nashua, United States
- Neptune City, United States
- Cedarhurst, United States
- Jamaica, United States
- New York, United States
- Rochester, United States
- Staten Island, United States
- Dayton, United States
- Oklahoma City, United States
- Scranton, United States
- Charleston, United States
- Austin, United States
- Dallas, United States
- DeSoto, United States
- Bellevue, United States
- Burgas, Bulgaria
- Kazanlak, Bulgaria
- Lovech, Bulgaria
- Novi Iskar, Bulgaria
- Sofia, Bulgaria
- Tserova Koria, Bulgaria
- Varna, Bulgaria
- Vratsa, Bulgaria
- Bełchatów, Poland
- Bialystok, Poland
- Gdansk, Poland
- Lublin, Poland
Questions about this study
Who is behind this study?
The study sponsor is Alkermes, Inc.
Did this study involve medication?
Yes. The study involved medication, including Samidorphan + olanzapine (ALKS 3831) and Placebo + olanzapine.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit me